HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ZTS
Zoetis Inc.
ZTS's fundamentals are mixed, but it looks cheap: trading at 14x earnings, about a third of its usual 37x. Analysts expect earnings to hold roughly steady.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ZTS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Strong | |
| Stable |
ZTS's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ZTS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 13x | $82.96 | — |
| Current | 14x | $82.96 | — |
| Cheap | 25x | $149 | +79% |
| Fair | 37x | $219 | +164% |
| Expensive | 47x | $275 | +232% |
Historical ranges are pointers, not guarantees.
ZTS's PE is in its cheap range at 14x. On analysts' estimates for next year's earnings, today's price would be 13x.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ZTS Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Stable | |
| Stable | |
| Stable | |
| Limited | |
| Moderate |
Analysts expect ZTS's earnings, revenue and profitability to hold roughly steady.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ZTS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.18 | +5.2% |
| Q3 2026 | $5.88 | -1% |
| Q2 2026 | $6.07 | +4.5% |
| Q1 2026 | $6.03 | +8.3% |
| Q4 2025 | $6.02 | +10% |
| Q3 2025 | $5.94 | +12% |
| Q2 2025 | $5.81 | +14% |
| Q1 2025 | $5.57 | +7.3% |
| Q4 2024 | $5.47 | +7.9% |
ZTS has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ZTS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ZTS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.4B | -0.4% |
| Q2 2026 | $2.5B | +0.3% |
| Q1 2026 | $2.3B | +1.9% |
| Q4 2025 | $2.4B | +3% |
| Q3 2025 | $2.4B | +0.5% |
| Q2 2025 | $2.5B | +4.2% |
| Q1 2025 | $2.2B | +1.4% |
| Q4 2024 | $2.3B | +4.7% |
ZTS's revenue grew through 2024 and has held roughly level since: $2.4B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -6.5 points |
| Q2 2026 | 35% | -1.6 points |
| Q1 2026 | 34% | -3 points |
| Q4 2025 | 32% | +0.3 points |
| Q3 2025 | 37% | +0.4 points |
| Q2 2025 | 37% | +3.6 points |
| Q1 2025 | 36% | +2.4 points |
| Q4 2024 | 32% | +2.2 points |
ZTS has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ZTS on cash flow, with more consistent year-over-year improvement.
ZTS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $717M | -11% |
| Q2 2026 | $538M | +75% |
| Q1 2026 | $291M | -34% |
| Q4 2025 | $732M | +6.2% |
| Q3 2025 | $805M | +2.7% |
| Q2 2025 | $308M | -17% |
| Q1 2025 | $438M | -3.7% |
| Q4 2024 | $689M | -1.4% |
ZTS's free cash flow has been positive every quarter for seven years: $2.3B over the past year, up 1.7% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has 234M diluted shares, down 6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ZTS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.5% | -6.1M shares |
| 1 year | -7.1% | -31.6M shares |
| 3 years | -11% | -49.8M shares |
| 5 years | -14% | -64.7M shares |
| Available history | -15% | -70.2M shares |
ZTS has the edge over HIMS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $500M |
| Q2 2026 | $584M |
| Q1 2026 | $606M |
| Q4 2025 | $2.1B |
| Q3 2025 | $394M |
| Q2 2025 | $338M |
| Q1 2025 | $443M |
| Q4 2024 | $553M |
ZTS spent $3.8B buying back its own shares over the past year, up 117% from the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ZTS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.2x | Moderate |
| Q2 2026 | 2.0x | Moderate |
| Q1 2026 | 1.9x | Healthy |
| Q4 2025 | 1.8x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 1.4x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.3x | Healthy |
ZTS's net debt is about 2.1 years of its operating earnings (EBITDA), up from 1.3 years a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ZTS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.0 | Neutral |
| Stochastic | 67.3 | Neutral |
ZTS's weekly RSI is 50 (neutral) and its Stochastic is 67 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ZTS PE vs Healthcare Sector
| Metric | ZTS | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 26x | 45% below |
| PE % | 7 | 29 | 22 pts below |
ZTS is trading at 14x earnings, a 45% discount to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ZTS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $77.3 | 7.4% above |
| 20 week MA | $76.0 | 9.2% above |
| 50 week MA | $96.6 | 14% below |
| 100 week MA | $125.5 | 34% below |
| 200 week MA | $151.4 | 45% below |
ZTS has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
ZTS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $133.3 | $160.7 | +21% |
| 2021 | $160.7 | $242.5 | +51% |
| 2022 | $242.5 | $145.8 | -40% |
| 2023 | $145.8 | $197.4 | +35% |
| 2024 | $197.4 | $164.6 | -17% |
| 2025 | $164.6 | $126.2 | -23% |
| 2026 YTD | $126.2 | $83.0 | -34% |
ZTS has the edge over HIMS on returns for 2026, with the stronger performance.